Progress in antisense technology

Annual Review of Medicine

Volumn 55, Issue , 2004, Pages 61-95

  Crooke, Stanley T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Double strand RNase; RNA; RNAi; RNase H; Therapeutics

Indexed keywords

ALICAFORSEN; ANTINEOPLASTIC AGENT; CGP 69846A; FOMIVIRSEN; GEMCITABINE; GENESENSE; ISIS 104838; ISIS 2503; ISIS 3521; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; SINGLE STRANDED DNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BINDING AFFINITY; CLINICAL TRIAL; DNA SYNTHESIS; DRUG FORMULATION; DRUG SCREENING; ENZYME STABILITY; GENE FUNCTION; GENOTOXICITY; HUMAN; HYBRIDIZATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MEDICAL ASSESSMENT; MEDICAL TECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA SPLICING; WATSON CRICK HYBRIDIZATION;

ANIMALS; BIOMEDICAL TECHNOLOGY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 1542269161     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.55.091902.104408     Document Type: Review

References (181)

1. Crooke ST. 2003. Oligonucleotide therapeutics. In Burger's Medicinal Chemistry, ed. DJ Abraham, pp. 115-66. New York: Wiley. 6th ed.
2. Crouch RJ, Dirksen M-L. 1985. Ribonucleases H. In Nucleuses, ed. SM Linn, RJ Roberts, pp. 211-41. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press
3. Crum C, Johnson JD, Nelson A, Roth D. 1988. Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translation in vitro. Nucleic Acids Res. 16:4569-81
4. Cerritelli SM, Frolova EG, Feng C, et al. 2003. Failure to produce mitochondrial DNA results in embryonic lethality in RNase H1 null mice. Mol. Cell 11:807-15
5. Donis-Keller H. 1979. Site specific enzymatic cleavage of RNA. Nucleic Acids Res. 7:179-92
6. Kawasaki AM, Casper MD, Freier SM, et al. 1993. Uniformly modified 2′-deoxy-2′-fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36:831-41
7. Sproat BS, Lamond AI, Beijer B, et al. 1989. Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. Nucleic Acids Res. 17:3373-86
8. Morvan F, Rayner B, Imbach JL. 1991. Alpha-oligonucleotides: a unique class of modified chimeric nucleic acids. Anticancer Drug Des. 6:521-29
9. Gagnor C, Rayner B, Leonetti JP, et al. 1989. Alpha-DNA.IX: parallel annealing of alpha-anomeric oligodeoxyribonucleotides to natural mRNA is required for interference in RNase H mediated hydrolysis and reverse transcription. Nucleic Acids Res. 17:5107-14
10. Miller PS. 1989. Non-ionic antisense oligonucleotides. In Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, ed. JS Cohen, p. 79. Boca Raton, FL: CRC Press
11. Maher LJ, III, Wold B, Dervan PB. 1989. Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation. Science 245:725-30
12. Stein CA, Cheng Y-C. 1993. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261:1004-12
13. Mirabelli CK, Bennett CF, Anderson KP, Crooke ST. 1991. In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anti-Cancer Drug Design 6:647-61
14. Cazenave C, Stein CA, Loreau N, et al. 1989. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Res. 17:4255-73
15. Quartin RS, Brakel CL, Wetmur JG. 1989. Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo-and endonuclease sensitivity and ability to form RNase H substrates. Nucleic Acids Res. 17:7253-62
16. Furdon PJ, Dominski Z, Kole R. 1989. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res. 17:9193-204
17. Eder PS, Walder JA. 1991. Ribonuclease H from K562 human erythroleukemia cells. J. Biol. Chem. 266:6472-79
18. Monia BP, Lesnik EA, Gonzalez C, et al. 1993. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:14514-22
19. Giles RV, Tidd DM. 1992. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res. 20:763-70
20. Crooke ST, Lemonidis KM, Neilson L, et al. 1995. Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J. 312:599-608
21. Lima WF, Crooke ST. 1997. Binding affinity and specificity of Escherichia coli RNase Hl: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry 36:390-98
22. Wu H, Lima WF, Crooke ST. 1998. Molecular cloning and expression of cDNA for human RNase H. Antisense Nucleic Acid Drug Dev. 8:53-61
23. Frank P, Braunshofer-Reiter C, Wintersberger U, et al. 1998. Cloning of the cDNA encoding the large subunit of human RNase HI, a homologue of the prokaryotic RNase HII. PNAS 95:12872-77
24. Kanaya S, Katsuda-Nakai C, Ikebara M. 1991. Importance of the positive charge cluster in Escherichia coli ribonuclease HI for the effective binding of the substrate. J. Biol. Chem. 266:11621-27
25. 2+-binding site. Proteins Struct. Fund. Genet. 17:337-46
26. Nicholson A. 1997. Ribonucleases: Structures and Functions. New York: Academic
27. Lima WF, Mohan V, Crooke ST. 1997. The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity. J. Biol. Chem. 272:18191-99
28. Wu H, Lima WF, Crooke ST. 1999. Properties of cloned and expressed human RNase H1. J. Biol. Chem. 274:28270-78
29. Lima WF, Crooke ST. 1997. Cleavage of single strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1. J. Biol. Chem. 272:27513-16
30. Fraser AG, Kamath RS, Zipperlen P, et al. 2000. Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature 408:325-30
31. Gonczy P, Echeverri C, Oegema K, et al. 2000. Functional genomic analysis of cell division in C. elegans using RNAi of genes on chromosome III. Nature 408:331-36
32. Grishok A, Tabara H, Mello CC. 2000. Genetic requirements for inheritance of RNAi in C. elegans. Science 287:2494-97
33. Zamore PD, Tuschl T, Sharp PA, Bartel DP. 2000. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101:25-33
34. Zamore PD. 2002. Ancient pathways programmed by small RNAs. Science 296:1265-69
35. Tuschl T, Zamore PD, Lehmann R, et al. 1999. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 13:3191-97
36. Caplen NJ, Fleenor J, Morgan AFA. 2000. dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference. Gene 252:95-105
37. Der SD, Yang Y-L, Weissmann C, Williams BRG. 1997. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc. Natl Acad. Sci. USA 94:3279-83
38. Elbashir SM, Harborth J, Lendeckel W, et al. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-98
39. Caplen NJ, Parrish S, Imani F, et al. 2001. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98:9742-47
40. Novina CD, Murray MF, Dykxhoorn DM, et al. 2002. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8:681-86
41. Vickers TA, Koo S, Bennett CF, et al. 2003. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. J. Biol. Chem. 278:7108-18
42. Cohen JS. 1993. Phosphorothioate oligodeoxynucleotides. See Ref. 42a, pp. 205-22
43. Crooke ST, Lebleu B, eds. 1993. Antisense Research and Applications. Boca Raton, FL: CRC Press
44. Crooke ST, Graham MJ, Zuckerman JE, et al. 1996. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277:923-37
45. Joos RW, Hall WH. 1969. Determination of binding constants of serum albumin for penicillin. J. Pharmacol. Exp. Ther. 166:113
46. Srinivasan SK, Tewary HK, Iversen PL. 1995. Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res. Dev. 5:131-39
47. Levin AA, Henry S, Monteith D, Templin M. 2001. Toxicity of antisense oligonucleotides. See Ref. 46a, pp. 201-67
48. Crooke ST, ed. 2001. Antisense Drug Technology: Principles, Strategies and Applications. New York: Marcel Dekker
49. Loke SL, Stein CA, Zhang XH, et al. 1989. Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA 86:3474-78
50. Hawley P, Gibson I. 1996. Interaction of oligodeoxynucleotides with mammalian cells. Antisense and Nucleic Drug Dev. 6:185-95
51. Crooke RM, Graham MJ, Cooke ME, Crooke ST. 1995. in vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J. Pharmacol. Exp. Ther. 275:462-73
52. Gao W-Y, Han F-S, Storm C, et al. 1992. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol. 41:223-29
53. Crooke ST. 1995. Oligonucleotide therapeutics. In Burger's Medicinal Chemistry and Drug Discovery, Vol. 1, ed. ME Wolff, pp. 863-900. New York: Wiley
54. Agrawal S, Temsamani J, Tang JY. 1991. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88:7595-99
55. Majumdar C, Stein CA, Cohen JS, et al. 1989. Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. Biochemistry 28:1340-46
56. Cheng Y, Gao W, Han F. 1991. Phosphorothioate oligonucleotides as potential antiviral compounds against human immunodeficiency virus and herpes viruses. Nucleosides Nucleotides 10:155-66
57. Stein CA, Neckers M, Nair BC, et al. 1991. Phosphorothioate oligodeoxycytidine interferes with binding of HTV-1 gp120 to CD4. J. Acquired Immune Deficiency Syndromes 4:686-93
58. Wyatt JR, Vickers TA, Roberson JL, et al. 1994. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. USA 91:1356-60
59. Hartmann G, Krug A, Waller-Fontaine K, Endres S. 1996. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by Heparin. Mol. Med. 2:429-38
60. Wickstrom E. 1986. Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods 13:97-102
61. Crooke ST. 1995. Therapeutic Applications of Oligonucleotides. Austin, TX: R.G. Landes. 138pp.
62. Hoke GD, Draper K, Freier SM, et al. 1991. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res. 19:5743-48
63. Campbell JM, Bacon TA, Wickstrom E. 1990. Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Methods 20:259-67
64. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267:1181-90
65. Crooke ST. 1993. Therapeutic potential of oligonucleotides. Curr. Opin. Invest. Drugs 2:1045-48
66. 3H-labeled oligonucleotides. II. 3′,5-blocked oligonucleotides. Mol. Pharmacol. 47:636-46
67. Miyao T, Takakura Y, Akiyama T, et al. 1995. Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice. Antisense Res. Dev. 5:115-21
68. Crooke RM. 1991. in vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-Cancer Drug Design 6:609-46
69. Crooke RM. 1993. in vitro and in vivo toxicology of first generation analogs. See Ref. 42a, pp. 471-92
70. Neckers LM. 1993. Cellular internalization of oligodeoxynucleotides. See Ref. 42a, pp. 451-60
71. Chrisey LA, Walz SE, Pazirandeh M, Campbell JR. 1993. Internalization of oligodeoxyribonucleotides by Vibrio parahaemolyticus. Antisense Res. Dev. 3:367-81
72. Tao LF, Marx KA, Wongwit W, et al. 1995. Uptake, intracellular distribution, and stability of oligodeoxynucleotide phosphorothioate by Schistosoma mansoni. Antisense Res. Dev. 5:123-29
73. Templin MV, Levin AA, Graham MJ, et al. 2000. Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev. 10:359-68
74. Leeds JM, Henry SP, Geary R, et al. 2000. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev. 10:435-41
75. Bennett CF, Chiang MY, Chan H, Grimm S. 1993. Use of cationic lipids to enhance the biological activity of antisense oligonucleotides. J. Liposome Res. 3:85-102
76. Bennett CF, Chiang MY, Chan H, et al. 1992. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1023-33
77. Quattrone A, Papucci L, Schiavone N, et al. 1994. Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids. Anti-Cancer Drug Design 9:549-53
78. Giles RV, Spiller DG, Tidd DM. 1995. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5:23-31
79. Wang S, Lee RJ, Cauchon G, et al. 1995. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA 92:3318-22
80. Iversen P. 1992. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anticancer Drug Des. 6:531-38
81. Yu RZ, Geary RS, Leeds JM, et al. 2000. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J. Pharm. Sci. 90:182-93
82. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269:89-94
83. 14C-labeled afovirsen sodium in patients with genital warts. Clin. Pharmacol. Ther. 56:641-46
84. 14C-labeled afovirsen sodium in patients with genital warts. Clin. Pharmacol. Ther. 56:641-46
85. Butler M, Stecker K, Bennett CF. 1997. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. 77:379-88
86. Rappaport J, Hanss B, Kopp JB, et al. 1995. Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney Int. 47:1462-69
87. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and phosphorothioate. Mol. Pharmacol. 45:932-43
88. Takakura Y, Mahato RI, Yoshida M, et al. 1996. Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Nucleic Acid Drug Dev. 6:177-83
89. Graham MJ, Crooke ST, Monteith DK, et al. 1998. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther. 286:447-58
90. Nyce JW. 1997. Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases. Exp. Opin. Invest. Drugs 6:1149-56
91. Nyce JW. 2001. Respirable antisense oligonucleotides (RASONs). See Ref. 46a, pp. 679-85
92. Saxena SK, Ackerman EJ. 1990. Microinjected oligonucleotides complementary to the α-sarcin loop of 28 S RNA abolish protein synthesis in Xenopus oocytes. J. Biol. Chem. 265:3263-69
93. Miner PB, Bane BL, Sadiq SA, et al. 2003. Antisense inhibitor of ICAM-1 given as enema improves symptomatic pouchitis. Presented at Digestive Disease Week, Orlando, FL
94. Chiang M-Y, Chan H, Zounes MA, et al. 1991. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266:18162-71
95. Agrawal S, Goodchild J, Civeira MP, et al. 1988. Oligodeoxynucleoside phosphoramidites and phosphorothioates as inhibitors of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 85:7079-83
96. Kulka M, Smith CC, Aurelian L, et al. 1989. Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4. Proc. Natl. Acad. Sci. USA 86:6868-72
97. Mirabelli CK, Crooke ST. 1993. Antisense oligonucleotides in the context of modern molecular drug discovery and development. See Ref. 42a, pp. 7-35
98. Crooke ST. 1992. Therapeutic applications of oligonucleotides. Bio/Technology 10:882-86
99. Bennett CF, Crooke ST. 1996. Oligonucleotide-based inhibitors of cytokine expression and function. In Therapeutic Modulation of Cytokines, ed. BB Henderson, W Mark, pp. 171-93. Boca Raton, FL: CRC Press
100. Azad RF, Driver VB, Tanaka K, et al. 1993. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37:1945-54
101. Wagner RW, Matteucci MD, Lewis JG, et al. 1993. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260:1510-13
102. Barton CM, Lemoine NR. 1995. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br. J. Cancer 71:429-37
103. Burgess TL, Fisher EF, Ross SL, et al. 1995. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA 92:4051-55
104. Hertl M, Neckers LM, Katz SI. 1995. Inhibition of interferon-gamma- induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-nonspecific effects. J. Invest. Dermatol. 104: 813-18
105. Crooke ST, Mirabelli CK. 1993. Antisense oligonucleotides in the context of modern molecular drug discovery and development. See Ref. 42a, pp. 7-35
106. Nagel KM, Holstad SG, Isenberg KE. 1993. Oligonucleotide pharmacotherapy: an antigene strategy. Pharmacotherapy 13:177-88
107. Crooke ST. 1998. Basic principles of antisense therapeutics. See Ref. 105a, pp. 1-50
108. Crooke ST, ed. 1998. Antisense Research and Application. Berlin/Heidelberg: Springer-Verlag
109. Simons M, Edelman ER, DeKeyser J-L, et al. 1992. Antisense c-myb oligonucleotides inhibit arterial smooth muscle cell accumulation in vivo. Nature 359:67-70
110. Abe J, Zhou W, Taguchi J, et al. 1994. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense CDC2 and CDK2 oligonucleotides in rat carotid artery. Biochem. Biophys. Res. Commun. 198:16-24
111. Whitesell L, Rosolen A, Neckers LM. 1991. In vivo modulation of N-myc expression by continous perfusion with an antisense oligonucleotide. Antisense Res. Dev. 1:343-50
112. Wahlestedt C, Pich EM, Koob GF, et al. 1993. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259:528-31
113. Wahlestedt C. 1994. Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol. Sci. 15:42-46
114. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 271:1462-70
115. Dean NM, McKay R, Condon TP, Bennett CF. 1994. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-I) mRNA by phorbol esters. J. Biol. Chem. 269:16416-24
116. Burch RM, Weitzberg M, Blok N, et al. 1991. N-(Fluorenyl-9- methoxycarbonyl) amino acids, a class of antiinflammatory agents with a different mechanism of action. Proc. Natl. Acad. Sci. USA 88:355-59
117. Higgins KA, Perez JR, Coleman TA, et al. 1993. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA 90:9901-5
118. Skorski T, Nieborowska-Skorska M, Nicolaides NC, et al. 1994. Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 91:4504-8
119. Hijiya N, Zhang J, Ratajczak MZ, et al. 1994. Biologic and therapeutic significance of MYB expression in human melanoma. Proc. Natl. Acad. Sci. USA 91:4499-503
120. Dean NM, McKay R. 1994. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91:11762-66
121. Dean N, McKay R, Miraglia L, et al. 1996. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res. 56:3499-507
122. Monia BP, Johnston JF, Geiger T, et al. 1995. Antitumor activity of a phosphorothioate oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2:668-75
123. Monia BP, Johnston JF, Sasmor H, Cummins LL. 1996. Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J. Biol. Chem. 271:14533-40
124. Nesterova M, Cho-Chung YS. 1995. A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth. Nat. Med. 1:528-33
125. Grillone L. 2001. The development of antisense oligonucleotides as antivirals. See Ref. 46a, pp. 725-38
126. Bennett F. 2001. General pharmacology of phosphorothioate oligodeoxynucleotides. See Ref. 46a, pp. 291-318
127. Shanahan W. 2001. ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1 (ICAM-1). See Ref. 46a, pp. 773-94
128. Maksymowych W, Blackburn W, Hutchings E, et al. 1999. A pilot study of ISIS 2302, an antisense oligodeoxynucleotide, in patients with active rheumatoid arthritis. Arthritis Rheumatol. 42:S170
129. Fredriksson T, Pettersson U. 1978. Severe psoriasis, oral therapy with a new retinoid. Dermatologica 157:238-44
130. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. 1998. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114:1133-42
131. Yu RZ, Su JG, Grundy JS, et al. 2003. Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimens. Antisense Nucleic Acid Drug Dev. 13:57-66
132. Yacyshyn B, Woloschuk B, Yacyshyn M, et al. 1997. Efficacy and safety of ISIS 2302 (ICAM-1 antisense oligonucleotide) treatment of steroid-dependent Crohn's disease. Presented at Annu. Meet. Am. Gastroenterol. Assoc. and Am. Assoc. Study Liver Dis., Washington, DC
133. Holmlund J. 2001. Clinical activities in patients with solid tumors or lymphoma. See Ref. 46a, pp. 739-59
134. Yuen A, Advani R, Fisher G, et al. 2001. A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer. Presented at Annu. Meet. Am. Soc. Clin. Oncol., San Francisco, CA
135. Lynch T, Raju R, Lind M, et al. 2002. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report. Presented at Annu. Meet. Am. Soc. Clin. Oncol., Orlando, FL
136. Waters J, Webb A, Cunningham D, et al. 2000. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 18:1812-23
137. Jansen B, Wacheck V, Heere-Ress E. 2000. Systemic treatment with Bcl-2 antisense down-regulates tumor content of Bcl-2 protein and induces major antitumor responses in patients with melanoma when combined with dacarbazine. Presented at Am. Assoc. Cancer Res. 91st Annu. Meet., San Francisco, CA
138. O'Dwyer PJ, Stevenson JP, Gallagher M, et al. 1999. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin. Cancer Res. 5:3977-82
139. Levin AA, Monteith DK, Leeds JM, et al. 1998. Toxicity of oligodeoxynucleotide therapeutic agents. See Ref. 105a, pp. 169-214
140. Galbraith WM, Hobson WC, Giclas PC, et al. 1994. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4:201-6
141. Henry SP, Giclas PC, Leeds J, et al. 1997. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechansim of action. J. Pharmacol. Exp. Ther. 281:810-16
142. Cornish KG, Iversen P, Smith L, et al. 1993. Cardiovascular effects of a phosphorothioate oligonucleotide to p53 in the conscious rhesus monkey. Pharmacol. Comm. 3:239-47
143. Henry SP, Monteith D, Levin AA. 1997. Antisense oligonucleotide inhibitors for the treatment of cancer. 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12:395-408
144. Henry SP, Novotny W, Leeds J, et al. 1997. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 7:503-10
145. Wallace TL, Bazemore SA, Kornbrust DJ, Cossum PA. 1996. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. J. Pharmacol. Exp. Ther. 278:1306-12
146. Griffin LC, Tidmarsh GF, Bock LC, et al. 1993. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81:3271-76
147. Nicklin PL, Ambler J, Mitchelson A, et al. 1997. Preclinical profiling of modified oligonucleotides: anticoagulation and pharmacokinetic properties. Nucleosides Nucleotides 16:1145-53
148. Sheehan JP, Lan H-C. 1998. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 92:1617-25
149. Henry S, Larkin R, Novotny W, Kornbrust D. 1994. Effects of ISIS 2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters. Pharm. Res. 11:S-353/S1-S490
150. Monteith DK, Geary RS, Leeds JM, et al. 1998. Preclinical evaluation of the effects of a novel antisense conpound targeting C-raf kinase in mice and monkeys. Toxicol. Sci. 46:365-75
151. Henry SP, Bolte H, Auletta C, Kornbrust DJ. 1997. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 120:145-55
152. Sarmiento UM, Perez JR, Becker JM, Ramaswamy N. 1994. In vivo lexicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. 4:99-107
153. Pisetsky DS, Reich CF. 1994. Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 54:101-7
154. Liang H, Nishioka Y, Reich CF, et al. 1996. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J. Clin. Invest. 98:1119-29
155. Lemonidis-Farrar K, Templin M, et al. 2000. Cytokine levels and cell population changes as predictive measures of immunostimulatory effects of phosphorothioate oligonucleotides (PS ODN) in mice. Toxicologist 42:120
156. Krieg AM. 1998. Immune stimulation by oligonucleotides. See Ref. 105a, pp. 243-62
157. Davis HL, Weeranta R, Waldschmidt TJ, et al. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:870-76
158. Harmann G, Krieg A. 2000. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164:944-53
159. Krieg AM, Yi A-K, Matson S, et al. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-49
160. Dorr FA, Glover JM, Kwoh J. 2001. Clinical safety of phosphorothioate oligodeoxynucleotides. See Ref. 46a, pp. 269-90
161. Nemunaitis J, Holmlund JT, Kraynak M, et al. 1999. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J. Clin. Oncol. 17:3586-95
162. Dorr A, Nemunaitis J, Bruce J, et al. 1999. Phase I and pharmacokinetic trial of ISIS 2503, a 20-mer antisense oligonucleotide against h-ras, by 14-day continuous infusion (CIV) in patients with advanced cancer. Presented at Annu. Meet. Am. Soc. Clin. Oncol., Atlanta, GA
163. Holmlund J, Nemunaitis J, Schiller J, et al. 1998. Phase I trial of c-raf antisense oligonucleotide - ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer. Presented at Annu. Meet. Am. Soc. Clin. Oncol., Los Angeles, CA
164. Sikic GI, Yuen AR, Halsey J, et al. 1998. A Phase I trial of an antisense oligonucleotide targeted to protein kinase C-alpha (ISIS 3521) delivered by twenty-one day continuous intravenous infusion. Presented at Annu. Meet. Am. Soc. Clin. Oncol., Denver, CO
165. Yuen AR, Halsey J, Fisher GA, et al. 1999. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. 5:3357-63
166. Summerton J, Weller D. 1997. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7:187-95
167. Crooke ST. 2001. Basic principles. See Ref. 46a, pp. 1-28
168. Stepkowski SM, Qu X, Wang M-E, et al. 2000. Inhibition of c-raf expression by antisense oligonucleotides extends heart allograft survival in rats. Transplantation 70:656-61
169. Zellweger T, Miyake H, Cooper S, et al. 2001. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J. Pharmacol Exp. Ther. 298:1-7
170. Dean NM, Butler M, Monia BP, Manoharan M. 2001. Pharmacology of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides. See Ref. 46a, pp. 319-38
171. Geary RS, Khatsenko O, Bunker K, et al. 2001. Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296:898-904
172. Manoharan M. 2001. Oligonucleotide conjugated in antisense technology. See Ref. 46a, pp. 391-470
173. Geary RS, Watanabe TA, Truong L, et al. 2001. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296:890-97
174. Crooke R, Graham M. 2001. Suborgan pharmacokinetics. See Ref. 46a, pp. 155-82
175. Zhang Z, Cook J, Nickel J, et al. 2000. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 18:862-67
176. Hardee G, Weinbach S, Tillman L. 2001. New routes and novel formulations for delivery of antisense oligonucleotides. See Ref. 46a, pp. 795-832
177. Nicklin PL, Craig SJ, Phillips JA. 1998. Pharmacokinetic properties of phosphorothioates in animals - absorption, distribution, metabolism and elimination. See Ref. 105a, pp. 141-68
178. Zhang R, Lu Z, Zhao H, et al. 1995. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. 50:545-56
179. Zhang R, Diasio RB, Lu Z, et al. 1995. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharmacol. 49:929-39
180. Henry SP, Stecker K, Brooks D, et al. 2000. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 292:468-79
181. Sewell L, Tami J, Geary R, et al. 2001. Phase I study of S.C and I.V. ISIS 104838 (anti-TNF-alpha), a second generation oligonucleotide. Presented at British Pharmaceutical Society, Dublin, Ireland